Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.44 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2452042 | 0.83 | PNMT (0.59) | PNMTOPRM1OPRL1AKR1C1HDAC4 | |
| SCHEMBL30934615 | 0.82 | OPRM1 (0.42) | PNMTOPRM1OPRL1AKR1C1HDAC4 | |
| SCHEMBL16407785 | 0.81 | MAPT (0.39) | PNMTDGAT1SOAT1TSHRLMNA | |
| SCHEMBL2453099 | 0.80 | PNMT (0.55) | PNMTOPRM1OPRL1AKR1C1HDAC4 | |
| SCHEMBL1502311 | 0.79 | MEN1 (0.51) | PNMTOPRM1OPRL1AKR1C1HDAC4 | |
| SCHEMBL2452508 | 0.77 | PNMT (0.52) | PNMTAKR1C1HDAC4DGAT1SOAT1 | |
| SCHEMBL12759763 | 0.77 | LMNA (0.38) | PNMTDGAT1SOAT1TSHRLMNA | |
| SCHEMBL12759755 | 0.77 | DGAT1 (0.36) | PNMTDGAT1SOAT1 | |
| SCHEMBL21130940 | 0.77 | PGR (0.46) | TSHRALDH1A1 | |
| SCHEMBL20743587 | 0.76 | PNMT (0.50) | PNMTOPRM1OPRL1AKR1C1HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-06-09 | — | — | US | disclosed |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-10-22 | — | — | US | disclosed |
| US-9120779-B2 | Inhibitors of HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2015-01-22 | — | — | US | disclosed |
| US-20110237579-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-7915252-B2 | Sulfonyl compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 | MERCK SHARP & DOHME (US) | 2011-03-29 | — | — | US | disclosed |
| US-20080318930-A1 | Sulfonyl Compound as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase-1 | MERCK SHARP & DOHME LLC | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318930-A1 | Sulfonyl Compound as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase-1 | HSD11B1, HSD17B1, HSD11B2 | PNMT 3006/4885OPRM1 1665/4885OPRL1 3610/4885 |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | PNMT 3609/4885OPRM1 3047/4885OPRL1 4476/4885 |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | PNMT 3609/4885OPRM1 3047/4885OPRL1 4476/4885 |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | PNMT 3836/4885OPRM1 2996/4885OPRL1 4467/4885 |
| US-20110237579-A1 | INHIBITORS OF HCV NS5A | MAVS, HAVCR2, EIF2AK2 | PNMT 3134/4885OPRM1 2882/4885OPRL1 3645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.